2019 Q1 Form 10-Q Financial Statement
#000156459019002298 Filed on February 07, 2019
Income Statement
Concept | 2019 Q1 | 2018 Q4 | 2017 Q4 |
---|---|---|---|
Revenue | $680.0K | $779.0K | $1.153M |
YoY Change | -38.46% | -32.44% | 0.17% |
Cost Of Revenue | $100.0K | $100.0K | $200.0K |
YoY Change | -64.29% | -50.0% | -4.76% |
Gross Profit | $580.0K | $679.0K | $953.0K |
YoY Change | -29.27% | -28.75% | 1.38% |
Gross Profit Margin | 85.29% | 87.16% | 82.65% |
Selling, General & Admin | $3.340M | $3.387M | $4.870M |
YoY Change | -24.6% | -30.45% | -12.25% |
% of Gross Profit | 575.86% | 498.82% | 511.02% |
Research & Development | $4.400M | $3.782M | $4.010M |
YoY Change | 10.83% | -5.69% | -20.12% |
% of Gross Profit | 758.62% | 557.0% | 420.78% |
Depreciation & Amortization | $160.0K | $250.0K | $310.0K |
YoY Change | -48.39% | -19.35% | -3.13% |
% of Gross Profit | 27.59% | 36.82% | 32.53% |
Operating Expenses | $7.740M | $7.169M | $8.870M |
YoY Change | -7.97% | -19.18% | -16.08% |
Operating Profit | -$7.160M | -$6.526M | -$7.917M |
YoY Change | -5.67% | -17.57% | -17.79% |
Interest Expense | $180.0K | $190.0K | $120.0K |
YoY Change | 28.57% | 58.33% | 140.0% |
% of Operating Profit | |||
Other Income/Expense, Net | $127.0K | ||
YoY Change | |||
Pretax Income | -$6.980M | -$6.400M | -$7.790M |
YoY Change | -6.31% | -17.84% | -18.68% |
Income Tax | $0.00 | $0.00 | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$6.980M | -$6.399M | -$7.791M |
YoY Change | -6.3% | -17.87% | -18.68% |
Net Earnings / Revenue | -1026.47% | -821.44% | -675.72% |
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$1.167M | -$1.102M | -$1.451M |
COMMON SHARES | |||
Basic Shares Outstanding | 119.5M | ||
Diluted Shares Outstanding |
Balance Sheet
Concept | 2019 Q1 | 2018 Q4 | 2017 Q4 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $36.48M | $35.22M | $47.34M |
YoY Change | -16.58% | -25.6% | -32.37% |
Cash & Equivalents | $36.48M | $35.35M | $47.34M |
Short-Term Investments | |||
Other Short-Term Assets | $1.050M | $530.0K | $890.0K |
YoY Change | -9.48% | -40.45% | 50.85% |
Inventory | $490.0K | $1.050M | $610.0K |
Prepaid Expenses | |||
Receivables | $503.0K | $550.0K | $1.170M |
Other Receivables | $60.00K | $120.0K | $260.0K |
Total Short-Term Assets | $38.57M | $37.47M | $50.27M |
YoY Change | -17.51% | -25.46% | -30.12% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $1.832M | $1.950M | $2.980M |
YoY Change | -34.29% | -34.56% | -24.37% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $138.0K | $270.0K | $310.0K |
YoY Change | -9.21% | -12.9% | 24.0% |
Total Long-Term Assets | $2.049M | $2.220M | $3.280M |
YoY Change | -33.19% | -32.32% | -21.72% |
TOTAL ASSETS | |||
Total Short-Term Assets | $38.57M | $37.47M | $50.27M |
Total Long-Term Assets | $2.049M | $2.220M | $3.280M |
Total Assets | $40.62M | $39.69M | $53.55M |
YoY Change | -18.47% | -25.88% | -29.66% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $628.0K | $650.0K | $450.0K |
YoY Change | 35.34% | 44.44% | -37.5% |
Accrued Expenses | $2.549M | $2.180M | $2.990M |
YoY Change | -23.71% | -27.09% | -3.24% |
Deferred Revenue | $525.0K | $580.0K | |
YoY Change | -21.41% | ||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $3.737M | $3.410M | $4.300M |
YoY Change | -19.77% | -20.7% | -3.15% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $590.0K | $600.0K | $660.0K |
YoY Change | 1.72% | -9.09% | -16.46% |
Total Long-Term Liabilities | $590.0K | $600.0K | $660.0K |
YoY Change | 1.72% | -9.09% | -16.46% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $3.737M | $3.410M | $4.300M |
Total Long-Term Liabilities | $590.0K | $600.0K | $660.0K |
Total Liabilities | $4.325M | $4.010M | $4.950M |
YoY Change | -17.48% | -18.99% | -5.35% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$260.8M | ||
YoY Change | 11.38% | ||
Common Stock | $297.1M | ||
YoY Change | 6.58% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $36.30M | $35.68M | $48.60M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $40.62M | $39.69M | $53.55M |
YoY Change | -18.47% | -25.88% | -29.66% |
Cashflow Statement
Concept | 2019 Q1 | 2018 Q4 | 2017 Q4 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$6.980M | -$6.399M | -$7.791M |
YoY Change | -6.3% | -17.87% | -18.68% |
Depreciation, Depletion And Amortization | $160.0K | $250.0K | $310.0K |
YoY Change | -48.39% | -19.35% | -3.13% |
Cash From Operating Activities | -$5.080M | -$3.950M | -$6.450M |
YoY Change | -9.45% | -38.76% | -8.51% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$40.00K | -$30.00K | -$30.00K |
YoY Change | -71.43% | 0.0% | -95.08% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $0.00 | $0.00 | $0.00 |
YoY Change | -100.0% | ||
Cash From Investing Activities | -$50.00K | -$20.00K | -$30.00K |
YoY Change | -61.54% | -33.33% | -95.45% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 6.320M | 1.850M | 3.090M |
YoY Change | 199.53% | -40.13% | -88.11% |
NET CHANGE | |||
Cash From Operating Activities | -5.080M | -3.950M | -6.450M |
Cash From Investing Activities | -50.00K | -20.00K | -30.00K |
Cash From Financing Activities | 6.320M | 1.850M | 3.090M |
Net Change In Cash | 1.190M | -2.120M | -3.390M |
YoY Change | -132.78% | -37.46% | -118.56% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$5.080M | -$3.950M | -$6.450M |
Capital Expenditures | -$40.00K | -$30.00K | -$30.00K |
Free Cash Flow | -$5.040M | -$3.920M | -$6.420M |
YoY Change | -7.86% | -38.94% | -0.31% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2018Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
127000 | |
CY2018Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
127000 | |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
747000 | ||
us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
0 | ||
CY2018Q1 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
185000 | |
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
CY2019Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
119493341 | |
CY2018Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
43726000 | |
CY2017Q4 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
1153000 | |
CY2018Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
883000 | |
CY2018Q4 | us-gaap |
Grants Receivable
GrantsReceivable
|
124000 | |
CY2018Q1 | us-gaap |
Grants Receivable
GrantsReceivable
|
145000 | |
CY2018Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
580000 | |
CY2018Q1 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
668000 | |
CY2018Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
27000 | |
CY2018Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
0 | |
CY2018Q1 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
19000 | |
CY2018Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
600000 | |
CY2018Q1 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
564000 | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
2411000 | ||
CY2018Q4 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
136000 | |
CY2017Q4 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
192000 | |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
381000 | ||
CY2018Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
35675000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3911000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
527000 | ||
onvo |
Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
|
260000 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
55000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-253000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-719000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-1293000 | ||
us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
260000 | ||
onvo |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
-113000 | ||
CY2017Q4 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
0 | |
us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
-63000 | ||
CY2018Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
44586000 | |
us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
50000 | ||
CY2017Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
127000 | |
onvo |
Stock Issued During Period Value Public Offering
StockIssuedDuringPeriodValuePublicOffering
|
6915000 | ||
CY2017Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
62878000 | |
onvo |
Stock Issued During Period Value Under Employee And Director Stock Option Rsu And Purchase Plans
StockIssuedDuringPeriodValueUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans
|
-135000 | ||
us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
74000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
826000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
7995000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-8502000 | ||
CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
43853000 | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-15413000 | ||
CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
47338000 | |
us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3911000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-27354000 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-63000 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
824000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
962000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5600000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-336000 | ||
onvo |
Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
|
-21000 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
207000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-637000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
183000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-1185000 | ||
us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-107000 | ||
onvo |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
-122000 | ||
us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
3000 | ||
us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
0 | ||
us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
0 | ||
us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
70000 | ||
onvo |
Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
|
6916000 | ||
onvo |
Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
|
7243000 | ||
us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
136000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
50000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
6830000 | ||
us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
0 | ||
us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-2000 | ||
us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
3000 | ||
us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
23000 | ||
us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note<font style="font-weight:normal;"> </font>1. Description of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Nature of operations</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Organovo Holdings, Inc., (“Organovo Holdings,” and collectively with its subsidiaries, “the Company”) is a biotechnology company pioneering a unique set of therapeutic and drug profiling capabilities based on its revolutionary ability to 3D bioprint liver tissues that emulate human biology and disease. The Company is developing its <font style="font-style:italic;">in vivo</font> liver tissues to treat end-stage liver disease and a select group of life-threatening, orphan diseases, for which there are limited treatment options other than organ transplantation. The Company’s program focused on an orphan disease known as Alpha-1-antitrypsin deficiency (“A1AT”), received the U.S. Food and Drug Administration’s (“FDA”) orphan drug designation in December 2017. The Company’s first Investigational New Drug Application (“IND”) filing is targeted for calendar-year 2020. Organovo Holdings is also capitalizing on its foundational ability to characterize highly specialized human cells and to build robust, functional human tissues by creating a range of novel <font style="font-style:italic;">in vitro</font> disease modeling platforms, including a broad set of non-alcoholic fatty liver disease (“NAFLD”) and non-alcoholic steatohepatitis (“NASH”) conditions. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except where specifically noted or the context otherwise requires, references to “Organovo Holdings,” “the Company,” “we,” “our,” and “us” in these notes to the condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiaries, Organovo, Inc., Samsara Sciences, Inc., and Organovo U.K., Ltd. In March 2018, the U.K. operations were combined with Organovo, Inc.’s operations.</p> | ||
us-gaap |
Cost Of Revenue
CostOfRevenue
|
400000 | ||
us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
136000 | ||
CY2018Q4 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
100000 | |
us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassification of prior year presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the adoption of the new accounting standard associated with clarifying presentation and classification in the statement of cash flows, certain reclassifications have been made to the prior period financial statements to conform with the current period presentation. These reclassifications did not have any effect on previously reported cash flows, net loss, or financial position. </p> | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates. Significant estimates used in preparing the condensed consolidated financial statements include those assumed in revenue recognition, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions.</p> | ||
CY2017Q4 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
200000 | |
us-gaap |
Cost Of Revenue
CostOfRevenue
|
700000 | ||
CY2018Q4 | us-gaap |
Dilutive Securities
DilutiveSecurities
|
0 | |
us-gaap |
Dilutive Securities
DilutiveSecurities
|
0 | ||
CY2017Q4 | us-gaap |
Dilutive Securities
DilutiveSecurities
|
0 | |
us-gaap |
Dilutive Securities
DilutiveSecurities
|
0 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
15600000 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
14000000 | ||
CY2018Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
8315000 | |
CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | |
CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | ||
CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7307 | |
CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.8071 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7299 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7686 | ||
CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0279 | |
CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0215 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | ||
CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.67 | |
CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.04 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.84 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.73 | ||
CY2018Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
25000000 | |
CY2018Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
10132312 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
8024194 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
4496763 | ||
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
622192 | ||
CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
13037551 | |
CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
4481218 | |
CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.01 | |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.29 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
4.21 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.08 | ||
CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
2.45 | |
CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
4.06 | |
CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
591082 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
561591 | ||
CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | |
CY2018Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
0 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y6M18D | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y6M18D | ||
CY2018Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
29290172 | |
onvo |
Operating Leases Monthly Rent Expense
OperatingLeasesMonthlyRentExpense
|
120000 | ||
CY2018Q4 | us-gaap |
Operating Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate
OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate
|
0.03 | |
onvo |
Office Space Area Under Lease Agreement
OfficeSpaceAreaUnderLeaseAgreement
|
45580 | ||
CY2018Q4 | onvo |
Landlord Funded Tenant Improvements
LandlordFundedTenantImprovements
|
500000 | |
CY2018Q1 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P36M | |
onvo |
Leasehold Improvements Funded By Lease Incentive
LeaseholdImprovementsFundedByLeaseIncentive
|
518000 | ||
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
264222000 | |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
1073027000 | |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
1104070000 | |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
1145861000 | |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
1183092000 | |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
1732566000 | |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
6502838000 |